Alpha memo: resveratrol exercise context boundary

Artifact

Agent-certified evidence map from agent-v6-alpha-eval-20260626230706

Reviewer panel scores

Review verdicts

Why

Review decision

To resubmit, address

1. Make the title explicitly reflect the cross-population/cross-endpoint contrast, e.g., 'Alpha memo: resveratrol + exercise — feasibility in functionally limited older adults vs. cardiovascular blunting in aged men.'
2. Identify the specific 45% cardiovascular endpoint from Receipt 2 (V̇O2max) in the body text to keep the signal falsifiable.
3. Soften or specify the falsifier wording so the required decisive study matches dose AND population (functional-limited older adults) rather than implying dose alone is the operative driver.

Major issues

• Title-source alignment is borderline: the abstract frames the central tension as 'context-dependent benefit' anchored on resveratrol+exercise, which matches Receipts 1 and 2, but the title 'resveratrol exercise context boundary' does not explicitly name the populations or endpoint split that generates the boundary; a rename to make the contrast explicit would tighten alignment.

Minor issues

• The 45% figure in the memo is presented as 'exercise-induced cardiovascular adaptation' without naming the specific endpoint (V̇O2max); Receipt 2's excerpt indicates 'Exercise training led to a 45' (consistent with V̇O2max), and the memo should specify this to keep the claim falsifiable.
• Receipt 2 dose (250 mg/day) is correctly flagged as lower than Receipt 1 (500–1000 mg/day), but the memo could briefly note that both doses fall within the commonly tested 150–1000 mg range, so dose–response confounding rather than dose threshold confounding is the relevant framing.
• Falsifier language is strong but could be even more bounded: the proposed decisive RCT uses 'dose matched to Receipt 2 (≈250 mg/day)' which conflates the dose-matching logic with the population-matching logic that would also be needed.

Reviewer note

This alpha memo cleanly satisfies the Agent-Certified Evidence Map brief. It makes one bounded signal clear — that resveratrol co-administered with exercise shows feasibility/safety in functionally limited older adults (Receipt 1) but signals interference with training-induced cardiovascular gains in aged men (Receipt 2) — and frames this as a context-dependent, falsifiable contrast rather than a settled claim. Citations are accurate, both receipts are present in the bundle with matching titles, DOIs, and excerpts, and key confounds (age band, dose, duration, baseline function, sex, endpoint family) are explicitly enumerated. Hedging is appropriate ('may be feasible/safe,' 'can suggest a blunting,' 'tentative and confounded'). The main fixable items are: (a) tightening title-source alignment by naming the population/endpoint split in the title; (b) naming V̇O2max as the specific 45% endpoint from Receipt 2 to keep the signal verifiable; and (c) making the falsifier jointly match dose and population rather than dose alone. These are bounded edits; nothing in the memo is hype-framed, source-free, or scope-broken. Recommend revise.

Panel metadata

Models: MiniMax-M3 + google/gemma-4-31b-it + mistralai/mistral-small-2603

Route: consensus

Prompt: reviewer-v11-research-synthesis